Real-time Adherence Monitoring for HIV Antiretroviral Therapy

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2010 Sep 3

PMID 20809380

Citations 146

Authors

Jessica E Haberer

Josh Kahane

Isaac Kigozi

Nneka Emenyonu

Peter Hunt

Jeffrey Martin

David R Bangsberg

Affiliations

Soon will be listed here.

Abstract

Current adherence assessments typically detect missed doses long after they occur. Real-time, wireless monitoring strategies for antiretroviral therapy may provide novel opportunities to proactively prevent virologic rebound and treatment failure. Wisepill, a wireless pill container that transmits a cellular signal when opened, was pilot tested in ten Ugandan individuals for 6 months. Adherence levels measured by Wisepill, unannounced pill counts, and self-report were compared with each other, prior standard electronic monitoring, and HIV RNA. Wisepill data was initially limited by battery life and signal transmission interruptions. Following device improvements, continuous data was achieved with median (interquartile range) adherence levels of 93% (87-97%) by Wisepill, 100% (99-100%) by unannounced pill count, 100% (100-100%) by self-report, and 92% (79-98%) by prior standard electronic monitoring. Four individuals developed transient, low-level viremia. After overcoming technical challenges, real-time adherence monitoring is feasible for resource-limited settings and may detect suboptimal adherence prior to viral rebound.

Citing Articles

Review of Impact of Risk Reduction Sessions on Sexual Behaviors in HIV Prevention Trials: Insights from Africa.

Wand H, Reddy T, Moodley J, Naidoo S, Ramjee G Arch Sex Behav. 2025; 54(2):805-815.

PMID: 39806191 DOI: 10.1007/s10508-024-03052-8.

A point-of-care tenofovir urine test improves accuracy of self-reported preexposure prophylaxis adherence and increases condomless sex reporting among young women.

Zewdie K, Muwonge T, Ssebuliba T, Bambia F, Nampewo O, Stein G AIDS. 2024; 38(14):1965-1971.

PMID: 39088310 PMC: 11524765. DOI: 10.1097/QAD.0000000000003988.

Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management: A Review.

Gackowski M, Jasinska-Stroschein M, Osmalek T, Waszyk-Nowaczyk M Med Sci Monit. 2024; 30:e944605.

PMID: 39012851 PMC: 11302205. DOI: 10.12659/MSM.944605.

A Pilot Randomized Control Trial of the Striving Towards EmPowerment and Medication Adherence (STEP-AD) Intervention for Black Women Living with HIV.

Dale S, Wright I, Madhu A, Reid R, Shahid N, Wright M AIDS Behav. 2024; 28(10):3483-3497.

PMID: 39012452 PMC: 11427489. DOI: 10.1007/s10461-024-04408-w.

Discrepancies between self-reported medication in adherence and indirect measurement adherence among patients undergoing antiretroviral therapy: a systematic review.

Liao R, Tang Z, Zhang N, Hu L, Chang Z, Ren J Infect Dis Poverty. 2024; 13(1):51.

PMID: 38970140 PMC: 11225374. DOI: 10.1186/s40249-024-01221-4.

References

Schumacher W, Frick E, Kauselmann M, Maier-Hoyle V, van der Vliet R, Babiel R . Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol. 2007; 38(4):304-12. DOI: 10.1016/j.jcv.2006.12.022. View

Hart J, Jeon C, Ivers L, Behforouz H, Caldas A, Drobac P . Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010; 54(2):167-79. PMC: 4022185. DOI: 10.1097/QAI.0b013e3181d9a330. View

Havlir D, Bassett R, Levitan D, Gilbert P, Tebas P, Collier A . Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA. 2001; 286(2):171-9. DOI: 10.1001/jama.286.2.171. View

Boyce J, Cooper T, Dolan M . Evaluation of an electronic device for real-time measurement of alcohol-based hand rub use. Infect Control Hosp Epidemiol. 2009; 30(11):1090-5. DOI: 10.1086/644756. View

Parienti J, Das-Douglas M, Massari V, Guzman D, Deeks S, Verdon R . Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008; 3(7):e2783. PMC: 2467488. DOI: 10.1371/journal.pone.0002783. View

Podsadecki T, Vrijens B, Tousset E, Rode R, Hanna G . Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2008; 196(12):1773-8. DOI: 10.1086/523704. View

Kahn J, Yang J, Kahn J . 'Mobile' health needs and opportunities in developing countries. Health Aff (Millwood). 2010; 29(2):252-8. DOI: 10.1377/hlthaff.2009.0965. View

Walji M, Coker O, Valenza J, Henson H, Warren-Morris D, Zhong L . A persuasive toothbrush to enhance oral hygiene adherence. AMIA Annu Symp Proc. 2008; :1167. View

Byakika-Tusiime J, Crane J, Oyugi J, Ragland K, Kawuma A, Musoke P . Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009; 13 Suppl 1:82-91. DOI: 10.1007/s10461-009-9546-x. View

10.

Bangsberg D, Hecht F, Charlebois E, Zolopa A, Holodniy M, Sheiner L . Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000; 14(4):357-66. DOI: 10.1097/00002030-200003100-00008. View

11.

Holden R, Karsh B . The technology acceptance model: its past and its future in health care. J Biomed Inform. 2009; 43(1):159-72. PMC: 2814963. DOI: 10.1016/j.jbi.2009.07.002. View

12.

Kerr T, Walsh J, Lloyd-Smith E, Wood E . Measuring adherence to highly active antiretroviral therapy: implications for research and practice. Curr HIV/AIDS Rep. 2005; 2(4):200-5. DOI: 10.1007/s11904-005-0017-3. View

13.

Intille S . Ubiquitous computing technology for just-in-time motivation of behavior change. Stud Health Technol Inform. 2004; 107(Pt 2):1434-7. View

14.

Hogg R, Heath K, Bangsberg D, Yip B, Press N, OShaughnessy M . Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002; 16(7):1051-8. DOI: 10.1097/00002030-200205030-00012. View

15.

Oyugi J, Byakika-Tusiime J, Charlebois E, Kityo C, Mugerwa R, Mugyenyi P . Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004; 36(5):1100-2. DOI: 10.1097/00126334-200408150-00014. View

16.

Bangsberg D, Perry S, Charlebois E, Clark R, Roberston M, Zolopa A . Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15(9):1181-3. DOI: 10.1097/00002030-200106150-00015. View

17.

Oyugi J, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C . Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007; 21(8):965-71. DOI: 10.1097/QAD.0b013e32802e6bfa. View

18.

Simoni J, Kurth A, Pearson C, Pantalone D, Merrill J, Frick P . Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 2006; 10(3):227-45. PMC: 4083461. DOI: 10.1007/s10461-006-9078-6. View

19.

Murtaugh C, Pezzin L, McDonald M, Feldman P, Peng T . Just-in-time evidence-based e-mail "reminders" in home health care: impact on nurse practices. Health Serv Res. 2005; 40(3):849-64. PMC: 1361171. DOI: 10.1111/j.1475-6773.2005.00388.x. View

20.

Bisson G, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L . Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008; 5(5):e109. PMC: 2386831. DOI: 10.1371/journal.pmed.0050109. View